EUVIMEDEUVIMED entdecken
Crossref

A Tumor Cell Membrane‐Coated CD40 Ligand‐Encoding Oncolytic Adenovirus Serves as a Potent Nano‐Vaccine for Ovarian Cancer Immunotherapy

Ying Li, Yuan Yuan, Yilin Dai, Shengfeng Xiong, Xinyuan Zhang, Zhoutong Dai, Ding Ma, Qinglei Gao, Fei Li iD

Advanced Healthcare Materials · 2026-04 · 15 (13)

DOI: 10.1002/adhm.202503175 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Healthcare Materials, online erschienen am 19.01.2026. Verfasst von Ying Li und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Adenoviridae, Immunotherapy, Oncolytic Viruses. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 58 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National Key R&D Program of China, Knowledge Innovation Program of Wuhan-Shuguang Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Oncolytic virus‐based vaccines for advanced ovarian cancer have limitations owing to their receptor‐dependent tropism, host immune clearance, and ascites‐mediated viral neutralization. To mitigate these drawbacks, a novel nano‐vaccine platform was developed by incorporating immunostimulatory oncolytic adenoviruses within tumor cell membranes. This biomimetic system enabled sustained antigen release and tumor‐localized delivery of co‐stimulatory molecules, creating immunological hotspots through in situ viral replication and PANoptosis. The nano‐vaccine achieved selective viral tropism with a 36.3:1 tumor‐to‐liver biodistribution ratio (vs. 1.0:1 for the uncoated virus) while resisting immune/ascites interference. Oncolysis triggered immunogenic cell death, which released damage‐associated molecular patterns and drove systemic antitumor immunity. Notably, the platform enriched stem‐like TCF1 + PD‐1 + CD8 + T cell reservoirs that demonstrate enhanced effector differentiation upon PD‐1 checkpoint blockade. In models of peritoneal carcinomatosis, combination therapy with αPD‐1 induced complete tumor eradication in 50% of mice and significantly prolonged survival. Furthermore, a synergistic efficacy was observed when the nano‐vaccine was administered with cisplatin, a frontline chemotherapeutic agent. This virotherapy paradigm synergizes vaccination and immune reprogramming to dismantle immunosuppressive networks, thereby offering transformative potential against ovarian cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ovarian NeoplasmsAdenoviridaeImmunotherapyOncolytic VirusesCancer VaccinesCD40 LigandCell MembraneFemaleAnimalsHumansMiceNanovaccinesCell Line, TumorOncolytic Virotherapy

Stichwörter der Autor:innen

CD40LDCadvanced ovarian cancernano‐vaccineoncolytic adenovirus

Substanzen

NanovaccinesCancer VaccinesCD40 Ligand

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • National Clinical Research Centre for Obstetrics and Gynecology, Cancer Biology Research Centre (Key Laboratory of the Ministry of Education), Tongji Hospital, Tongji Medical College, Huazhong University of Science and…

ORCID-Profile: Fei Li

Förderung

  • National Natural Science Foundation of China
  • National Key R&D Program of China
  • Knowledge Innovation Program of Wuhan-Shuguang Project
  • National Key Research and Development Program of China

Zitieren

APA

Li, Y., Yuan, Y., Dai, Y., Xiong, S., Zhang, X., Dai, Z., Ma, D., Gao, Q., & Li, F. (2026). A Tumor Cell Membrane‐Coated CD40 Ligand‐Encoding Oncolytic Adenovirus Serves as a Potent Nano‐Vaccine for Ovarian Cancer Immunotherapy. Advanced Healthcare Materials, 15(13). https://doi.org/10.1002/adhm.202503175

Vancouver

Li Y, Yuan Y, Dai Y, Xiong S, Zhang X, Dai Z, et al. A Tumor Cell Membrane‐Coated CD40 Ligand‐Encoding Oncolytic Adenovirus Serves as a Potent Nano‐Vaccine for Ovarian Cancer Immunotherapy. Advanced Healthcare Materials. 2026;15(13). doi:10.1002/adhm.202503175

BibTeX
@article{Li2026,
  author = {Li, Ying and Yuan, Yuan and Dai, Yilin and Xiong, Shengfeng and Zhang, Xinyuan and Dai, Zhoutong and Ma, Ding and Gao, Qinglei and Li, Fei},
  title = {A Tumor Cell Membrane‐Coated CD40 Ligand‐Encoding Oncolytic Adenovirus Serves as a Potent Nano‐Vaccine for Ovarian Cancer Immunotherapy},
  journal = {Advanced Healthcare Materials},
  year = {2026},
  volume = {15},
  number = {13},
  doi = {10.1002/adhm.202503175}
}
Kostenlos starten →